Overview

FITMI - First In Treating Male Infertility

Status:
Recruiting

Trial end date:
2025-09-30

Target enrollment:

Participant gender:

Summary

This RCT aims to assess whether treatment with Denosumab can improve semen quality in infertile men selected by serum AMH as a positive predictive biomarker.

Phase:

Phase 2

Details

Lead Sponsor:

Martin Blomberg Jensen

Treatments:

Denosumab